109786-75-6

Upstream product

• 6553-96-4 2,4,6-triisopropylphenylsulfonyl chloride 
• 109786-74-5 (R)-3-(4-methoxybenzyloxy)propane-1,2-diol 
• 824-94-2 p-methoxybenzyl chloride 
• 109786-73-4 (S)-4-[(4-methoxybenzyloxy)methyl]-2,2-dimethyl-1,3-dioxolane 
• 109786-76-7 (R)-4-(((4-methoxybenzyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolane 

Downstream Products

• 84727-35-5 (S)-α-<<(4-methoxyphenyl)methoxy>methyl>-1H-imidazole-1-ethanol 
• 109837-87-8 (R)-α-<<(4-methoxyphenyl)methoxy>methyl>-1H-imidazole-1-ethanol 
• 109837-88-9 6-[(R)-2-Imidazol-1-yl-1-(4-methoxy-benzyloxymethyl)-ethoxy]-2,2-dimethyl-hexanoic acid 
• 109837-89-0 6-[(S)-2-Imidazol-1-yl-1-(4-methoxy-benzyloxymethyl)-ethoxy]-2,2-dimethyl-hexanoic acid 

Relevant academic research and scientific papers

Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (±)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4 methoxyphenyl)-methoxy]methyl]ethoxy]hexanoic acids

A series of substituted ω-[2-(1H-imidazol-1-yl)ethoxy]alkanoic acid derivatives were synthesized and evaluated for their ability to inhibit thromboxane synthase both in vitro and in vivo. Compound 13 was identified as a potent and selective competitive in